Key result
Apolipoprotein E ε4 carriers were referred to a specialized lipid clinic at a younger age and had a poorer total cholesterol reduction compared to non-carriers.
Why the study?
Is the apoE ε4 polymorphism associated with younger age at referral to a lipid clinic and poorer response to lipid-lowering therapy in patients with dyslipidemia?
Observational (n=463)
No
Is the apoE ε4 polymorphism associated with younger age at referral to a lipid clinic and poorer response to lipid-lowering therapy in patients with dyslipidemia?
ApoE ε4 carriers with dyslipidemia are referred to specialized clinics at a younger age and exhibit a blunted cholesterol-lowering response to statin therapy compared to non-carriers.
Answers are grounded in this paper and cite their sources.
ε4 carriers may need earlier referral and closer statin monitoring; leaves open whether genotyping improves dyslipidemia outcomes.
BACKGROUND: The risk of coronary heart disease (CHD) is related to environmental factors and genetic variants. Apolipoprotein E (apoE) polymorphisms are heritable determinants of total and low-density lipoprotein cholesterol, with some authors suggesting an association between the ε4 allele and CHD. We investigated the relationship between apoE genotype and age at referral to a specialized lipid clinic by the primary care physician and whether the benefits of treatment with statin differed between genotypes. METHODS: We assessed individual apoE genotypes and lipid blood profile in a total of 463 patients followed at a specialized lipid clinic due to dyslipidemia, with a 3-year median follow-up time. The primary care physician at the time of the referral had no access to the apoE genotyping results. Carriers of apoE ε4/ε2 genotype were excluded. RESULTS: The frequencies of ε2, ε3 and ε4 alleles were 7.8, 78.9 and 13.3%, respectively. There were no significant differences between genders. Although with similar lipid profiles and antidyslipidemic drug usage at baseline, ε4-carriers were referred to the clinic at a younger age (44.2 ± 14.7 years) compared with non-ε4 carriers (50.6 ± 13.8 years) (p < 0.001), with a substantially younger age of referral for homozygous E4/4 and for all genotypes with at least one copy of the ε4 allele (p < 0.001 for trend). Although both ε4 and non-ε4 carriers achieved significant reductions in total cholesterol during follow-up (p < 0.001 vs. baseline), the mean relative decrease in total cholesterol levels was higher in non-ε4 carriers (-19.9 ± 2.3%) compared with ε4 carriers (-11.8 ± 2.3%), p = 0.003. CONCLUSION: Our findings support the concept that there is a reduced response to anti-dyslipidemic treatment in ε4 carriers; this can be a contributing factor for the earlier referral of these patients to our specialized lipid clinic and reinforces the usefulness of apoE genotyping in predicting patients response to lipid lowering therapies.
No takes yet. Share an insight, caveat, or question.
Baptista et al. (2011) conducted an observational in Dyslipidemia (n=463). Apolipoprotein E epsilon-4 (apoE ε4) carrier status vs. Non-ε4 carriers was evaluated on Age at referral (p=<0.001). Apolipoprotein E ε4 carriers were referred to a specialized lipid clinic at a younger age and had a poorer total cholesterol reduction compared to non-carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: